A non-interventional, post authorization safety study (PASS) to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe. Sobi.Anakin-201 (PASS Kineret CAPS)

21/08/2014
28/11/2023
EU PAS number:
EUPAS6366
Study
Finalised
Documents
Study protocol
Initial protocol
English (345.53 KB - PDF) View document
Study results
Study results
English (137.68 KB - PDF) View document
Study report
Other information
ENCePP Seal
Signed checklist for study protocols
English (465.87 KB - PDF) View document